Payment overview · 2025
General Payments
$1,891.72
70 reported records · 17 companies
Healthcare provider profile · identity verified
Vanvan Baoha Nguyen, PA-C
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant|Medical · HENDERSON, NV · NPI 1336737360
Verified facts
What the public records show
CMS Open Payments records show Vanvan Baoha Nguyen, PA-C received $1,891.72 in general payments during 2025 across 70 reported records.
Intra-Sana Laboratories accounted for 20.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 30 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Intra-Sana Laboratories | Unresolved — no canonical attribution shown | $386.27 | 20.4% | 10 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $352.00 | 18.6% | 11 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $291.50 | 15.4% | 13 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $201.18 | 10.6% | 9 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $112.48 | 6.0% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $108.20 | 5.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $90.97 | 4.8% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $77.64 | 4.1% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $65.27 | 3.5% | 4 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $45.61 | 2.4% | 3 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $44.46 | 2.4% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $26.56 | 1.4% | 1 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $21.11 | 1.1% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $20.19 | 1.1% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $16.26 | 0.9% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $16.02 | 0.8% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.00 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,891.72 | 70 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| GLYCATE Normalized: glycate |
Drug | Intra-Sana Laboratories | $386.27 | 10 | 2025 |
Source payment records
|
|||||
| RELTONE 200 MG Normalized: reltone 200 mg |
Drug | Intra-Sana Laboratories | $386.27 | 10 | 2025 |
Source payment records
|
|||||
| RELTONE 400 MG Normalized: reltone 400 mg |
Drug | Intra-Sana Laboratories | $386.27 | 10 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $187.04 | 7 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $171.90 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $149.38 | 5 | 2025 |
Source payment records
|
|||||
| DEXCOM G7 GSS (161) Normalized: dexcom g7 gss 161 |
Medical Supply | Dexcom, Inc. | $144.07 | 1 | 2025 |
Source payment records
|
|||||
| DEXCOM STELO GLUCOSE BIOSENSOR Normalized: dexcom stelo glucose biosensor |
Not specified | Dexcom, Inc. | $144.07 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $112.48 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $111.02 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $108.20 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $65.27 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $65.27 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $61.43 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $61.43 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $57.19 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $57.11 | 8 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $45.61 | 3 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $45.61 | 3 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $44.46 | 3 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $29.54 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $26.56 | 1 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $21.11 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $20.45 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $20.19 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16.26 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $16.02 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $16.02 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $16.00 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $8.92 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 36 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
36 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
56 | 27 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 332 | 159 |
| Amlodipine Besylate | Amlodipine Besylate | 155 | 67 |
| Lisinopril | Lisinopril | 140 | 70 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 132 | 57 |
| Losartan Potassium | Losartan Potassium | 123 | 55 |
| Metformin Hcl | Metformin Hcl | 120 | 56 |
| Levothyroxine Sodium | Levothyroxine Sodium | 115 | 41 |
| Hydrochlorothiazide | Hydrochlorothiazide | 74 | 38 |
| Famotidine | Famotidine | 66 | 32 |
| Ibuprofen | Ibuprofen | 60 | 31 |
| Alendronate Sodium | Alendronate Sodium | 59 | 28 |
| Gabapentin | Gabapentin | 59 | 33 |
| Omeprazole | Omeprazole | 58 | 31 |
| Jardiance | Empagliflozin | 56 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 49 | 26 |
| Trazodone Hcl | Trazodone Hcl | 49 | 23 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 46 | 24 |
| Simvastatin | Simvastatin | 42 | 18 |
| Ozempic | Semaglutide | 40 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 40 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 39 | 17 |
| Montelukast Sodium | Montelukast Sodium | 39 | 18 |
| Farxiga | Dapagliflozin Propanediol | 36 | 16 |
| Carvedilol | Carvedilol | 34 | 15 |
| Glipizide | Glipizide | 33 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 33 | 21 |
| Meloxicam | Meloxicam | 29 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 29 | suppressed |
| Eliquis | Apixaban | 28 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | 13 |
| Pantoprazole Sodium | Pantoprazole Sodium | 28 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 26 | 12 |
| Methylprednisolone | Methylprednisolone | 26 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 25 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | 13 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 22 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 21 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 21 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 20 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 19 | 16 |
| Ondansetron Odt | Ondansetron | 19 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 18 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 17 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Lidocaine | Lidocaine | 17 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 17 | suppressed |
| Atenolol | Atenolol | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 16 | suppressed |
| Azithromycin | Azithromycin | 15 | 13 |
| Potassium Chloride | Potassium Chloride | 15 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Allopurinol | Allopurinol | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,891.72 · 70 records | Intra-Sana Laboratories | AIRSUPRA, BREZTRI, Cologuard Collection Kit, DEXCOM G7 GSS (161), DEXCOM STELO GLUCOSE BIOSENSOR, Dexcom G6 Transmitter, FARXIGA, Flexitouch Plus, GLYCATE, INJECTAFER, KRYSTEXXA, Kerendia, MOUNJARO, Nimbl, OTEZLA, Ozempic, QULIPTA, RELTONE 200 MG, RELTONE 400 MG, REPATHA, Rybelsus, Symbravo, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, Veozah, XIFAXAN, YUPELRI, ZEPBOUND, ZORYVE | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error